RxDoctor Payments Data

Louis Caruso, MD

Cardiovascular Disease · Germantown, TNNPI 1811918287

Payments from drug & device makers

$9,151in general payments, 2019–2025

Across 498 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Amgen$1K
  • Novartis$1K
  • Johnson & Johnson$877
  • Pfizer$734
  • Actelion Pharmaceuticals US, Inc.$529
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$9,01799%
  • Education$1341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,151 in reported general payments places this provider in the 70th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$134,112
Medicare patients
609
Services billed
1,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban441$357,859
EntrestoSacubitril/Valsartan201$189,327
OpsumitMacitentan12$152,521
Repatha SureclickEvolocumab142$106,910
JardianceEmpagliflozin100$83,534
XareltoRivaroxaban79$67,361
FarxigaDapagliflozin Propanediol79$49,258
Praluent PenAlirocumab59$42,080
BrilintaTicagrelor31$16,794
VerquvoVericiguat11$15,118
Repatha PushtronexEvolocumab16$11,090
CorlanorIvabradine Hcl11$8,137
Metoprolol Succinate340$4,114
Atorvastatin Calcium301$4,038
Rosuvastatin Calcium269$3,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$734$357,859441 claims
NovartisEntresto$1,080$189,327201 claims
Actelion Pharmaceuticals US, Inc.Opsumit$529$152,52112 claims
Boehringer IngelheimJardiance$453$83,534100 claims
Johnson & JohnsonXarelto$877$67,36179 claims
AstraZenecaFarxiga, Brilinta$325$66,052110 claims
MerckVerquvo$472$15,11811 claims
AmgenCorlanor$1,273$8,13711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →